Metoprolol Succinate Extended Release Tablets — Class II drug recall D-0129-2019
Terminated recall by Teva Pharmaceuticals USA, reported 2018-10-31, distributed nationwide. Failed dissolution specifications: Out-of-Specification dissolution test result obtained during routine stabil
| Recall number | D-0129-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, North Wales, PA, United States |
| Recall initiated | 2018-10-19 |
| Classified | 2018-11-01 |
| Reported by FDA | 2018-10-31 |
| Terminated | 2019-04-03 |
| Distributed | Nationwide (US) |
| Quantity | 53,451 bottles |
| Reason classes | specification failure |
| NDC | 62037-0831-01 |
| Lot numbers | 1220211M |
| Expiration dates | 2019-02 |
Product
Metoprolol Succinate Extended Release Tablets, USP 50 mg, 100-count bottle, Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, NDC 62037-831-01
Reason for recall
Failed dissolution specifications: Out-of-Specification dissolution test result obtained during routine stability testing.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0129-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.